Auto-generated event page

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)

Score 41 low confidence 1 source posts Updated Feb 25, 2026, 12:50 AM UTC

Track This Event Open Event in App More Signal Pages

Cluster sources

Newest source rows first.

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

GlobeNewswire Public Companies • Feb 25, 2026, 12:30 AM UTC

Entity focus

Direct link to post

https://pushme.site/signals/132037-junshi-biosciences-announces-strategic-collaboration-with-antengene-to-e?utm_source=signal-132037&utm_medium=social&utm_campaign=signal-pages&utm_content=hero

Quick distribution loop

Step 1

Post this live link in threads where users ask how to monitor this event.

Step 2

Point readers to "Track This Event" for immediate conversion into an alert.

Step 3

Reuse entity keywords from this page for targeted follow-up replies.

Back to signal pages Open query hub